NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference
21 nov. 2023 08h00 HE
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy,...
NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
06 nov. 2023 16h03 HE
|
NeuroPace, Inc.
Third quarter 2023 revenue of $16.4 million, an increase of 47% year-over-year Full-year revenue guidance increased to $62.5-$63.5 million, up from $59-$61 million Cash burn reduced to $2.2 million...
NeuroPace Announces RNS System Enhancements Designed to Streamline Care
17 oct. 2023 16h05 HE
|
NeuroPace, Inc.
- Upgraded nSight Platform Improves Clinicians’ Ability to Track, Review and Evaluate Patient Data - - ‘Simple Set Programming’ Enables Complete Programming Set Transfer Directly to RNS Tablet - -...
NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023
16 oct. 2023 17h01 HE
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy,...
NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference
20 sept. 2023 16h05 HE
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy,...
NeuroPace to Participate in Upcoming Investor Conferences
24 août 2023 16h05 HE
|
NeuroPace, Inc.
- Wells Fargo 2023 Healthcare Conference - - Morgan Stanley 21st Annual Global Healthcare Conference - - Lake Street Capital Markets 7th Annual Best Ideas Growth Conference - MOUNTAIN VIEW, Calif.,...
NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
08 août 2023 16h03 HE
|
NeuroPace, Inc.
Second quarter 2023 revenue of $16.5 million increased 62% year-over-year Full-year revenue guidance increased to $59-$61 million, up from $52-54 million Cash burn reduced to $4 million in the...
NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market
19 juil. 2023 16h03 HE
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy,...
NeuroPace to Report Second Quarter 2023 Financial Results on August 8, 2023
18 juil. 2023 16h05 HE
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy,...
NeuroPace Announces CEO Transition
28 juin 2023 16h03 HE
|
NeuroPace, Inc.
NeuroPace Appoints Joel Becker as President & CEO Becker Brings a Track Record of Strong Commercial Execution and Deep Medical Device Operating Expertise Mike Favet to leave Company after four...